G3139 (oblimersen sodium)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for G3139 (oblimersen sodium), covering 2011-11-07 to 2013-02-11. Get the full timeline:
Most recent: Clinical Trial Update: Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer [Phase 1, Phase 2]